

CORPORATE PRESENTATION

J.P. Morgan Health Care Conference 2020 / San Francisco, CA

Prof. Dr. Hermann Lübbert, CEO Thomas Schaffer, CFO January 2020



This presentation contains forward-looking statements including, without limitation, statements containing the words "expects", "future", "potential" and words of similar import. Such forward looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable forward-looking statements include statements regarding growth in market size, revenue potential, sources of future revenues, timing of regulatory submissions, receipt of regulatory approvals, results of clinical trials, timing of product introductions and commercialization, expansion in the US market and future capital needs forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of Biofrontera AG, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements These risks include, without limitation, unanticipated delays or disruptions in clinical trials, potential need to expand, add or extend clinical trials, potentially unfavorable trial results, delays in regulatory submissions and approvals, potential denials of regulatory approval, changes in regulatory requirements, adverse events with patients, product liability, potential lack of demand, introduction of superior products by competitors, lack of adequate reimbursement, challenges in establishing distribution channels, potential manufacturing challenges, potential inability to manufacture products cost-effectively, costs and challenges of planned US expansion, failure to raise necessary funds on a timely basis which may prevent us from completing the development and commercialization of our products and product candidates or have other material adverse effects on our business, potential intellectual property infringement, potential inadequacy of our intellectual property portfolio, dependence on key employees and suppliers, dependence on the reliability and integrity of information technology systems, potential shareholder dilution, fluctuations in currency rates and other factors referenced in this presentation Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements Biofrontera AG disclaims any obligation to update these forward looking statements to reflect future events or developments.

BIOFRONTERA AT-A-GLANCE



HEADQUARTER	PRODUCTS	SALES FORCE	FINANCIAL PERFORMANCE	STOCK MARKET
Headquartered in Leverkusen, Germany; US-headquarter in Woburn, MA	Biofrontera's PDT drug Ameluz® is approved in the U.S., EU, Switzerland and Israel	Dedicated sales teams in the U.S., Germany, Spain and the UK	Strong revenue growth: doubling of annual revenue year-over-year for the past 3 years	Listed on the Frankfurt Exchange (B8F) and Nasdaq (BFRA)
	In the U.S. Biofrontera also markets the new topical antibiotic Xepi™			

Corporate strategy

Optimizing the market potential of Ameluz[®] and Xepi™, positioning Biofrontera amongst the most innovative specialty pharmaceutical companies in dermatology.

NON-MELANOMA SKIN CANCER



Epidemiology¹

- BCC: >4 million BCC treatments annually in the U.S.
- AK: >58 million patients in the U.S., particularly the elderly population
- SCC: second most dangerous skin cancer after melanoma

Progression 2,3,4

- Recent data show that mild or even invisible AK has a higher chance of progression to SCC than severe (with strong hyper-keratosis) AK
- If an AK lesion progresses to SCC, it does so in about 2 years on average



Sources:

- I. http://www.skincancer.org/skin-cancer-information
- Schmitz et al., J EurAcadDermatolVenereol. 2016 Aug;30(8):1303-7
- Fernández-Figueraset al., J EurAcadDermatolVenereol. 2015 May;29(5):991-7
- 4. Fuchs & Marmur, DermatolSurg. 2007 Sep;33(9):1099-101

PRODUCTS

AMELUZ® IS A GEL FORMULATION FOR TOPICAL USE



80810rig1s000LBL.pdf




* Pending in the U.S.

META-ANALYSIS OF ALL AK TREATMENT OPTIONS AVAILABLE IN EUROPE



Significant superiority of Ameluz[®] over Metvix[®] was proven in phase III trials and is documented in the EMA approved Ameluz[®] SmPC (PI)



- The relative efficacy of different treatment options for mild to moderate actinic keratosis (including cryotherapy, topicals and PDT options) was analyzed in a European meta-analysis (Vegter & Tolley 2014).
- Although this study was a meta-analysis of placebo-controlled trials, rather than a head-to-head comparison of treatments, we believe this data shows significant support for PDT with Ameluz[®] as the best available treatment for mild to moderate actinic keratosis on the face and scalp. Source: Vegter & Tolley, PlosOne 2014, June, Vol. 9, Issue 6

COMPETITIVE ENVIRONMENT IN THE U.S.

AMELUZ[®] VS. LEVULAN[®]



FDA-approved prescribing information of both drugs		Ameluz® / LED lamps (ITT)*	Levulan® / Blu-U® (ITT)**
	Patient clearance: 3 months after last of 1 or 2 PDTs	84-91%	66-69%
Efficacy	Patient clearance scalp	65-82%	50%
	Patient clearance: 12 (Ameluz) or 10-12 (Levulan) months after last of 1 or 2 PDTs	53-69%	31%
Convenience	Formulation (easier and faster application of gel)	Gel (tube)	Liquid (stick)
	Illumination time	10 min	16 min + 40 sec
	Incubation time	3 hrs	14-18 hrs
	Skin rejuvenation	Phase III data	No phase III data
Indications & potential		Field and lesion	Lesion
	Approved treatment area	Head and scalp	Head, scalp, upper extremities
	Superficial and nodular BCC	High efficacy in phase III	No data

* three phase III studies

** two phase III studies and one open-label study


AK MARKET IN THE EU

POSITION AMELUZ[®] AS THE #1 PDT DRUG AND EXPAND THE PDT MARKET



EU - Strategy

- Position Ameluz[®] as the **#1 PDT drug** (achieved in Germany and Spain)
- Expand the PDT market through daylight PDT to compete with topical drugs
 - Average ex-factory price per tube of Ameluz[®]: EUR 150
 - Dermatologists in Europe have favored topical prescriptions due to lack of reimbursement for procedures such as PDT
 - Recent approval to market Ameluz[®] for use in combination with daylight PDT enables patients to obtain reimbursement more easily
 - Cryotherapy is unpopular due to perceived poor efficacy, high recurrence rates, bad cosmetic outcome and lack of reimbursement




* Share of cryotherapy estimated since no reliable data available **IMS data 2016

AK MARKET IN THE U.S.

POSITION AMELUZ[®] AS THE #1 PDT DRUG AND EXPAND THE PDT MARKET

US - Strategy

- Position Ameluz[®] as the **#1 PDT drug**
- Expand PDT market by taking away market share from topicals and cryotherapy
 - List price per tube of Ameluz®: US\$ 285
 - 3% PDT treatments of the AK market represent annual PDT drug sales of estimated US\$ 130 million
 - Most U.S. dermatologists have traditionally preferred cryotherapy due to more favorable reimbursement
 - New CPT codes and medical need for field therapy is now more favorable for PDT



Biofrontera

Deep in dermatology

REIMBURSEMENT OF PDT WITH AMELUZ®



CPT-codes (Jan 2019)

Avg. payment to dermatologist in USD

Efficacy rates	Avg. payment to dermatologist
PDT performed by other health care workers	\$126
PDT without debridement, by qualified health care professional (corresponding to USPI of Levulan)	\$205
PDT with debridement (i.e. targeted curettage, abrasion), by qualified health care professional (USPI of Ameluz®)	\$261
Cryotherapy capped at >14 lesions	\$155

The Centers for Medicare and Medicaid Services (CMS) have assigned new CPT-codes, which make the use of PDT financially more rewarding for doctors.

PRODUCTS

XEPI™ IS THE FIRST NEW TOPICAL ANTIBIOTIC TO ENTER THE US-MARKET IN OVER 10 YEARS





XEPI[™]: TOPICAL ANTIBIOTICS MARKET IN THE U.S.



Short-term strategy:


- 1) Position Xepi™ (ozenoxacin) as the #1 choice for topical antibiotic prescribed by dermatologists
- 2) Take away market share from generic topical antibiotics
- Dermatologists write 10% of all prescriptions for generic topical antibiotics.
- Dermatologists issue ~ 1 million prescriptions annually; most prescriptions per patient among all specialty physicians.
- Pediatric dermatologists serve as opinion leaders for pediatricians.

Long-term strategy:

- 1) Focus on pediatricians with \sim 1.7 MM prescriptions annually
- 2) Establish Xepi[™] as the first choice in skin and soft tissue infections
- 3) Expand Xepi™ label beyond Impetigo through clinical program

Estimated market size: 10.8 million prescriptions annually

Generic mupirocin (topical antibiotic) prescription share by specialty



Data Source: IMS - NPA MAT July 2018

DEVELOPMENT PIPELINE




Biofrontera's strategy is to optimize the market potential and market positioning of Ameluz[®] before investing in the development of additional products.

Product	Indication / comments	Torritory	Pre-clinical	Clin	Clinical Phase		Submitted	Status
		Territory	Fle-cillical		II	III	Subilitteu	Status
Ameluz®	Actinic keratosis (AK), field cancerization	EU, CH, IL	٠	•	•	•	•	On market
Ameluz®	AK, lesion- and field-directed	US	•	•	•	•	•	On market
Ameluz®	Basal cell carcinoma	EU	٠	•	•	•	٠	On market
Ameluz®	AK: Daylight PDT	EU/CH	•	•	•	•	•	On market
Ameluz®	AK: Trunk & extremities	EU/US	٠	•	•	•	٠	Phase III completed
Ameluz®	Basal cell carcinoma	US	•	•	•	•		Phase III ongoing
Ameluz®	Squamous cell carcinoma in situ	EU/US	٠	•	•			Phase III in preparation
Ameluz®	Acne	EU/US	•	•	•			Phase II in preparation



PRODUCT SALES





STOCK MARKETS

BIOFRONTERA SHARES



Key stock information

Listing	Frankfurt	Nasdaq	
Ticker Symbol	B8F	BFRA	
Price per Share (as of Jan 7, 2020) 1 ADS = 2 common shares	€4.85 per share	US\$ 10,34 per ADS	
52 Week High-Low	€8.02 - €4.05	\$18.32 - \$9.00	
Shares Outstanding	44,849,365		
Market Cap (as of Jan 7, 2020)	~US\$ 243 M		

Analyst coverage

Financial Institution	Analyst
Benchmark & Co	Bruce Jackson
Lake Street Capital	Thomas Flaten
sc-consult GmbH	Holger Steffen


2019 share price development: B8F



SHAREHOLDERS

SHAREHOLDER STRUCTURE





Shares outstanding: 44,849,365

Shareholder structure:

- Two major investors, each holding about 30%
- About 40% free float, including institutional investors and family offices in Europe and the U.S.

INVESTMENT OPPORTUNITY



Our goal is to optimize the positioning and market potentials of Ameluz[®] and Xepi™, while becoming a leading specialty pharmaceutical company in dermatology.

PRODUCTS	PIPELINE	COMMERCIALIZATION	FINANCIAL PERFORMANCE	STOCK MARKET
Ameluz®: superior PDT drug for non-melanoma skin cancer	Very low development risk due to approved products	Commercialization of Ameluz® in major pharmaceutical markets	Strong revenue growth and healthy balance sheet	Solid share price development
Xepi™: first new topical antibiotic on the US- market in over 10 years	Additional indications with similarly high market potentials possible	Multi-billion \$ market opportunity with Ameluz® and Xepi™ in the U.S. alone		Listings on major global stock markets

CONTACT US

CONTACT DETAILS



Prof. Hermann Lübbert, PhD CEO & Founder h.luebbert@biofrontera.com

Thomas Schaffer CFO t.schaffer@biofrontera.com

Pamela Keck Head of IR p.keck@biofrontera.com

Biofrontera AG Hemmelrather Weg 201 D-51377 Leverkusen Germany
 Phone
 +49 (214) 876 32 -0

 Fax
 +49 (214) 876 32 -90

 Email
 ir@biofrontera.com

 www.biofrontera.com